Fabry's disease

Jump to navigation Jump to search

Template:DiseaseDisorder infobox

WikiDoc Resources for Fabry's disease

Articles

Most recent articles on Fabry's disease

Most cited articles on Fabry's disease

Review articles on Fabry's disease

Articles on Fabry's disease in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Fabry's disease

Images of Fabry's disease

Photos of Fabry's disease

Podcasts & MP3s on Fabry's disease

Videos on Fabry's disease

Evidence Based Medicine

Cochrane Collaboration on Fabry's disease

Bandolier on Fabry's disease

TRIP on Fabry's disease

Clinical Trials

Ongoing Trials on Fabry's disease at Clinical Trials.gov

Trial results on Fabry's disease

Clinical Trials on Fabry's disease at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Fabry's disease

NICE Guidance on Fabry's disease

NHS PRODIGY Guidance

FDA on Fabry's disease

CDC on Fabry's disease

Books

Books on Fabry's disease

News

Fabry's disease in the news

Be alerted to news on Fabry's disease

News trends on Fabry's disease

Commentary

Blogs on Fabry's disease

Definitions

Definitions of Fabry's disease

Patient Resources / Community

Patient resources on Fabry's disease

Discussion groups on Fabry's disease

Patient Handouts on Fabry's disease

Directions to Hospitals Treating Fabry's disease

Risk calculators and risk factors for Fabry's disease

Healthcare Provider Resources

Symptoms of Fabry's disease

Causes & Risk Factors for Fabry's disease

Diagnostic studies for Fabry's disease

Treatment of Fabry's disease

Continuing Medical Education (CME)

CME Programs on Fabry's disease

International

Fabry's disease en Espanol

Fabry's disease en Francais

Business

Fabry's disease in the Marketplace

Patents on Fabry's disease

Experimental / Informatics

List of terms related to Fabry's disease

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Fabry disease (also known as Anderson-Fabry disease, Angiokeratoma corporis diffusum, Ceramide trihexosidosis, and Sweeley-Klionsky disease) is an X-linked recessive inherited lysosomal storage disease.

Pathophysiology

A deficiency of the enzyme alpha galactosidase A causes a glycolipid known as globotriaosylceramide (also abbreviated as Gb3, GL-3, or ceramide trihexoside) to accumulate within the blood vessels, other tissues, and organs. This accumulation leads to an impairment of their proper function. The condition affects hemizygous males, as well as both heterozygous and homozygous females; males tend to experience the most severe clinical symptoms, while females vary from virtually no symptoms to those as serious as males. This variability is thought to be due to X-inactivation patterns during embryonic development of the female.

Symptoms

Symptoms include anhidrosis, fatigue, and red spots on skin. Some of the most common pathological symptoms includes skin lesions (angiokeratomas), and a burning pain of the extremities. This pain can become very intense, especially when one has a fever. Angiokeratomas are tiny, painless papules that appear at any region of the body, but are predominant on the thighs, buttocks, lower abdomen, and groin. Ocular involvement may be present showing cornea verticillata (also known as vortex keratopathy); this corneal whorling does not have any effect on vision or eye function. Symptoms are typically first experienced in early childhood and can be very difficult to understand; the rarity of Fabry disease to many clinicians sometimes leads to misdiagnoses or ignorance. Manifestations of the disease usually increase in number and severity as an individual ages.

Kidney complications are a common and serious effect of the disease; renal insufficiency and renal failure may worsen throughout life. Proteinuria is often the first sign of kidney involvement. Cardiac complications occur when Gb3 builds up in different heart cells; heart related effects worsen with age and may lead to increased risk of heart disease. Cerebrovascular effects lead to an increased risk of stroke. Other symptoms include an inability or decreased ability to sweat, fatigue, ringing in the ears (tinnitus), vertigo, nausea, and diarrhea.

Fabry's disease may also have ocular involvement, such as the presence of corneal verticillata in the basal layers of the epithelium, conjunctival aneursyms, and spokelike cataracts. Papilledema, macular edema, optic atrophy and retinal vascular dilation may also be present.

Treatment

Until recently, treatment of Fabry disease targeted the symptomatic effects. However, it is currently being treated at the cellular level through enzyme replacement therapy using Agalsidase alpha (Replagal) and Agalsidase beta (Fabrazyme®). The cost of these drugs is problematic (approximately $170,000 US a year/patient) and remains a barrier to many patients in some countries. Enzyme replacement therapy (typically infused every two weeks) may be performed in the patient's home by the patients themselves. Enzyme replacement therapy is not a cure, and must be infused recurrently for maximum benefit.

Eponym

  • It is named for Johannes Fabry.[1]

References

External links

Template:SIB

de:Morbus Fabry fi:Fabryn tauti

Template:WikiDoc Sources